Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.

摘要: Temozolomide (TMZ) is an oral alkylating agent which widely used in the treatment of glioblastoma (GBM) and composed astrocytic and/or oligodendroglial tumors, evaluation O(6) -methylguanine DNA methyltransferase (MGMT) expression important to predict response TMZ therapy. In this study, we conducted immunohistochemical analysis 117 cases Japanese GBM including 19 with oligodendroglioma component (GBMO), using a scoring system for quantitative staining intensity proportion MGMT, performed survival these patients. Immunohistochemically, 55 (47%) were positive MGMT various intensities proportions (total score (TS) ≥ 2), while 62 (53%) negative (TS = 0). The distribution pattern was not affected by any clinicopathological parameters such as histological subtype (GBM vs. GBMO), age gender. patients revealed that minimal (TS ≥ 2) significant unfavorable prognostic factor (P < 0.001) well resectability (P = 0.004). Moreover, multivariate showed most potent independent predictor progression free also overall patient (P < 0.001). This first report employing both evaluate GBM. addition, our results emphases values approach glioma routine laboratory examination.